- Home
- KZIA vs ONCY Comparison
KZIA vs ONCY Comparison
Compare KZIA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | ONCY |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 98.7M |
| IPO Year | 2002 | 2002 |
Fundamental Metrics
Financial Performance| Metric | KZIA | ONCY |
|---|---|---|
| Price | $14.63 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $19.50 | $7.33 |
| AVG Volume (30 Days) | 188.8K | ★ 1.7M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $0.69 |
| 52 Week High | $17.40 | $1.51 |
Technical Indicators
Market Signals| Indicator | KZIA | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 52.50 |
| Support Level | $5.62 | $0.90 |
| Resistance Level | $17.40 | $1.18 |
| Average True Range (ATR) | 1.06 | 0.06 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 89.70 | 58.04 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.